Whole Genomes on the Rise | GenomeWeb

Whole Genomes on the Rise

Premium

James Lupski participated in the 1986 Molecular Biology of Homo sapiens meeting at Cold Spring Harbor Laboratory, during which the initial discussions arose over whether researchers should sequence the entire human genome. Twenty-two years later, he was part of the team that deciphered the first personal genome sequence, that of the CSHL meeting organizer — and co-discoverer of the structure of DNA — James Watson. And now Lupski is the lead author on the first study ever to use next-generation whole-genome sequencing to identify the cause of a Mendelian disease: his own.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.

Mar
30
Sponsored by
SeraCare

Our roundtable of industry experts will provide an overview of the current regulatory landscape for clinical genomics tests.

Apr
13
Sponsored by
SeraCare

In this webinar, Gregory J. Tsongalis of Dartmouth Hitchcock Medical Center will discuss how his lab developed and validated a cancer hotspot assay.